Stay updated on Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page.

Latest updates to the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page
- Check6 days agoChange DetectedThe clinical trial record for pembrolizumab combined with BCG in high-risk bladder and upper-tract urothelial cancer is displayed, including study design, eligibility criteria, treatment arms, and outcome measures.SummaryDifference51%

- Check13 days agoChange DetectedThe footer’s site revision label changed from v3.7.2 to v3.8.0 while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedA general NIH website-transition notice was added above the ClinicalTrials.gov navigation, and the site revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe displayed site revision changed from v3.7.0 to v3.7.1 while the page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study record content, with a minimal header and footer. This indicates that access to the study details is blocked and the content is not available for review.SummaryDifference18%

- Check62 days agoChange DetectedThe page's revision label updated to Revision: v3.7.0, replacing Revision: v3.6.6; this reflects a page version update without altering the study information.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs BCG in High-Risk NMIBC & NMI-UTUC Clinical Trial page.